CN116507370A - 使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗神经元疾病的方法 - Google Patents

使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗神经元疾病的方法 Download PDF

Info

Publication number
CN116507370A
CN116507370A CN202180066844.4A CN202180066844A CN116507370A CN 116507370 A CN116507370 A CN 116507370A CN 202180066844 A CN202180066844 A CN 202180066844A CN 116507370 A CN116507370 A CN 116507370A
Authority
CN
China
Prior art keywords
aimp2
leu
vector
promoter
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066844.4A
Other languages
English (en)
Chinese (zh)
Inventor
崔镇宇
白京和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genelotti Inc
Original Assignee
Genelotti Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelotti Inc filed Critical Genelotti Inc
Publication of CN116507370A publication Critical patent/CN116507370A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180066844.4A 2020-09-30 2021-09-30 使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗神经元疾病的方法 Pending CN116507370A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085950P 2020-09-30 2020-09-30
US63/085,950 2020-09-30
PCT/IB2021/059017 WO2022070141A1 (en) 2020-09-30 2021-09-30 METHODS OF TREATING NEURONAL DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
CN116507370A true CN116507370A (zh) 2023-07-28

Family

ID=80949780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066844.4A Pending CN116507370A (zh) 2020-09-30 2021-09-30 使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗神经元疾病的方法

Country Status (9)

Country Link
US (1) US20230374092A1 (https=)
EP (1) EP4221759A4 (https=)
JP (1) JP2023544141A (https=)
KR (1) KR20230079267A (https=)
CN (1) CN116507370A (https=)
AU (1) AU2021354996A1 (https=)
CA (1) CA3192710A1 (https=)
MA (1) MA71714A (https=)
WO (1) WO2022070141A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166777A (zh) * 2019-03-15 2021-07-23 杰内罗蒂股份有限公司 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
KR101067816B1 (ko) * 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
KR101749138B1 (ko) * 2015-10-07 2017-06-20 원광대학교산학협력단 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
US10716866B2 (en) * 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR102349061B1 (ko) * 2019-03-15 2022-01-10 주식회사 제너로스 생착능이 증가된 줄기세포의 제조 방법
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166777A (zh) * 2019-03-15 2021-07-23 杰内罗蒂股份有限公司 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
CN113166777B (zh) * 2019-03-15 2025-09-12 杰内罗蒂股份有限公司 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途

Also Published As

Publication number Publication date
CA3192710A1 (en) 2022-04-07
WO2022070141A1 (en) 2022-04-07
KR20230079267A (ko) 2023-06-05
AU2021354996A9 (en) 2023-04-27
US20230374092A1 (en) 2023-11-23
JP2023544141A (ja) 2023-10-20
EP4221759A1 (en) 2023-08-09
MA71714A (fr) 2025-05-30
AU2021354996A1 (en) 2023-04-20
EP4221759A4 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
JP7503590B2 (ja) 遺伝子構築物
KR100575251B1 (ko) ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
US7989606B2 (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function
CN113166777B (zh) 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
JP2023055906A (ja) アンジェルマン症候群の遺伝子治療法のための改変ｕｂｅ３ａ遺伝子
US11865189B2 (en) Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degeneration
CN116507370A (zh) 使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗神经元疾病的方法
CN116406304A (zh) 使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗年龄相关的黄斑疾病的方法
WO2022055320A1 (ko) 표적화된 유전자 전달을 위한 아데노-부속 바이러스 벡터
WO2019035919A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING L-PLASTINE ACTIVITY IN OSTEOCLASTES TO REDUCE BONE LOSS
KR102626543B1 (ko) AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터
US20250281573A1 (en) Methods of Treating Retinal Degenerative Diseases Using AIMP2-DX2 and Optionally a Target Sequence for miR-142 and Compositions Thereof
WO2006047233A2 (en) Pink-1 promoter
KR20250021203A (ko) Kras 단백질 안정성 조절 기반 항암 치료기술
EA048975B1 (ru) Векторы, содержащие aimp2-dx2 и целевые нуклеиновые кислоты для mir-142, и их применение
HK1252168B (en) Genetic construct

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination